Category: Stada
-
EPO Board of Appeal revokes Novo Nordisk’s cardiovascular semaglutide patent; generics could enter EU as early as 2031
The Board found the claims lacked priority, so a clinical study publication destroyed novelty, leaving Ozempic and Wegovy potentially vulnerable to competition earlier than expected.
-
Double jeopardy takes down Sanofi’s cabazitaxel use patent as UPC’s Munich LD revokes after EPO BoA affirmance
Lawyers representing generics makers welcomed the UPC’s decision to revoke the patent regardless of a prior EPO decision to the contrary.